
About Immunai:
Immunai is an AI-driven platform company focused on improving drug discovery and development by decoding the human immune system.
We combine large-scale single cell immune data, advanced machine learning, and strong engineering to help pharmaceutical and research partners make better, more informed decisions throughout the drug development process.
Our long-term goal is to reduce drug development failure rates and help more effective medicines reach patients. We’re building this platform thoughtfully and collaboratively, bringing together expertise across biology, AI, engineering, and business.
Immunai is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
About the role:
As a Computational Biologist II at Immunai, you will be working in a fast-paced and research-driven external collaborations team to lead projects with our pharma, biotech, and academic partners. Through this position, you will have the opportunity to work with biologists, immunologists, computational biologists, machine learning specialists, and the business development team to design, execute, and disseminate data analyses leveraging single cell multi-omics for immuno-oncology and autoimmune disease research applications.
Location: New York, NY (Hybrid model)
Reporting to Associate Director, Computational Biology
What will you do?
Required qualifications:
Desired personal traits:
Compensation: This position offers a base salary typically between $130,000 - $150,000. There is an opportunity to consider higher compensation above this range based on business need, candidate experience, and or skills.
*Please note that when you apply for a position at Immunai, your application will be processed via our recruitment platform Spark Hire. You can read more about how we process personal data here: https://www.immunai.com/privacy-policy/

Comprehensively mapping and decoding the immune system with single-cell biology and AI to power new therapeutic discoveries, accelerate drug development and improve patient outcomes